SMITHS FALLS, ON
and MADRID, March 19, 2018
/CNW/ - Canopy Growth Corporation (TSX: WEED)
("Canopy Growth" or "the Company") is pleased to confirm that it
has successfully completed a transfer of 1,500 cannabis clones to
its Madrid-based partner,
Alcaliber SA ("Alcaliber"), completing the first phase of a
partnership entered into by both parties (the "Parties") as
announced on September 11, 2017.
Canopy Growth and Alcaliber enjoy a very strong and committed
partnership which will continue to see Alcaliber producing cannabis
genetics supplied by Canopy Growth subsidiaries for
commercialization purposes.
Canopy Growth also wishes to clarify that, contrary to certain
speculation, the Company is not in negotiations to acquire
Alcaliber.
"Our view of the European continent mirrors our Canadian
expansion strategy," said Bruce
Linton, Chairman and CEO, Canopy Growth. "We're diversifying
our production capabilities on the continent in anticipation of
rapid European market expansion. In addition to a large licenced
production footprint in Odense,
Denmark we are working closely with our partner Alcaliber to
capture market share by scaling supply."
The successful transfer marks the third continent with Canopy
Growth genetics growing in soil today.
Here's to Future Growth (not just export) in Europe and beyond.
About Canopy Growth Corporation
Canopy Growth is a
world-leading diversified cannabis and hemp company, offering
distinct brands and curated cannabis varieties in dried, oil and
Softgel capsule forms. From product and process innovation to
market execution, Canopy Growth is driven by a passion for
leadership and a commitment to building a world-class cannabis
company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector
names including cannabis icon Snoop Dogg, breeding legends DNA
Genetics and Green House seeds, and Fortune 500 alcohol leader
Constellation Brands, to name but a few. Canopy Growth
operates seven cannabis production sites with over 1 million square
feet of production capacity, including over 500,000 square feet of
GMP-certified production space. The Company has operations in seven
countries across four continents. The Company is proudly dedicated
to educating healthcare practitioners, conducting robust clinical
research, and furthering the public's understanding of cannabis,
and through its partly owned subsidiary, Canopy Health Innovations,
has devoted millions of dollars toward cutting edge,
commercializable research and IP development. Through partly owned
subsidiary Canopy Rivers Corporation, the Company is providing
resources and investment to new market entrants and building a
portfolio of stable investments in the sector. From our historic
public listing to our continued international expansion, pride in
advancing shareholder value through leadership is engrained in all
we do at Canopy Growth. For more information
visit www.canopygrowth.com
Notice Regarding Forward Looking Statements
This news
release contains forward-looking statements. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "expects" or "does not expect", "is expected",
"estimates", "intends", "anticipates" or "does not anticipate", or
"believes", or variations of such words and phrases or state that
certain actions, events or results "may", "could", "would", "might"
or "will" be taken, occur or be achieved. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Canopy Growth Corporation, its subsidiaries, or its
affiliates to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Examples of such statements include
future operational and production capacity, the impact of enhanced
infrastructure and production capabilities, and forecasted
available product selection. The forward-looking statements
included in this news release are made as of the date of this news
release and Canopy Growth Corporation does not undertake an
obligation to publicly update such forward-looking statements to
reflect new information, subsequent events or otherwise unless
required by applicable securities legislation.
Neither the TSX Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Canopy Growth Corporation